top of page

야외 모임

Communication

Prof. Jae-Hyung Park and Dong-kyu Cho selected as regular members of KAST

Prof. Jae-Hyung Park and Dong-kyu Cho selected as regular members of KAST

Nov 20, 2022

The 'stem cell' challenge continues in the 'osteoarthritis' treatment market

The 'stem cell' challenge continues in the 'osteoarthritis' treatment market

Sep 27, 2022

Exostemtech applied for phase 1 clinical trial IND in Korea for an exosome-based osteoarthritis trea

Apr 21, 2022

Humedix and Exostemtech signed an agreement for joint development of exosome treatment

Humedix and Exostemtech signed an agreement for joint development of exosome treatment

Apr 5, 2022

Daewoong Pharmaceutical and ExostemTech, joint development agreement for exosome treatment

Daewoong Pharmaceutical and ExostemTech, joint development agreement for exosome treatment

Jan 6, 2022

[Jump-Up Bio] Exostemtech said, "The first clinical trial in Korea next year...He's even going to ge

Nov 19, 2021

"The strength of Exostemtech is…World-class exosome mass production, analysis, and quality managemen

"The strength of Exostemtech is…World-class exosome mass production, analysis, and quality managemen

Nov 14, 2021

Exostemtech, a "exosome treatment," attracts 10 billion won in series B investment (Korea economy)

Oct 26, 2021

Exostemtech, Cancer Exosome Inhibitor Clinical Full-scale (The Bell)

Jul 19, 2021

Exostemtech approved phase 1 and 2a clinical trials for combination of Kitruda and Exosome inhibitor

Jul 16, 2021

bottom of page